文献速递妇科

局部晚期宫颈癌放化疗反应蛋白组学预测模型

Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer.
PubMed 文献 · Gynecol Oncol · 2020-02-24

研究前瞻性获取181例局部晚期宫颈癌患者放化疗前冷冻组织样本,用反向蛋白阵列检测22种总蛋白和磷酸化蛋白,基于BCL2、HER2、CD133、CAIX和ERCC1建立预测模型。该模型对总生存和无进展生存的预测C-index分别为0.86和0.62(临床模型),风险评分为独立预测因子。

要点

  • BCL2、HER2、CD133、CAIX和ERCC1蛋白组合可独立预测局部晚期宫颈癌放化疗后生存。
  • 蛋白组学模型预测总生存C-index为0.86,优于临床模型0.62。
  • 风险评分为无进展生存(HR 1.6)和总生存(HR 2.1)的独立预测因子。

核心结论

  • BCL2、HER2、CD133、CAIX和ERCC1蛋白组合可独立预测局部晚期宫颈癌患者放化疗后的生存。

研究设计与样本

  • 前瞻性获取181例局部晚期宫颈癌患者放化疗前冷冻组织样本。
  • 用反向蛋白阵列检测22种总蛋白和磷酸化蛋白表达水平。
  • 选定蛋白经蛋白质印迹和免疫组化验证,模型进行内部和外部验证。

主要发现

  • 基于BCL2、HER2、CD133、CAIX和ERCC1的无监督聚类将患者分为三组,总生存(P=0.001)和无进展生存(P=0.003)不同。
  • 反向蛋白阵列结果与蛋白质印迹结果显著相关(R2=0.856)。
  • 模型预测总生存的C-index为0.86,临床模型为0.62;预测无进展生存的C-index为0.82,临床模型为0.64。
  • Kaplan-Meier曲线显示风险评分对无进展生存和总生存的预后意义呈剂量依赖。
  • 多变量Cox模型证实风险评分为无进展生存(HR: 1.6; 95% CI: 1.4-1.9; P < 0.001)和总生存(HR: 2.1; 95% CI: 1.7-2.5; P < 0.001)的独立预测因子。

临床怎么用

  • 该蛋白组学模型有助于识别对放化疗有反应的肿瘤,改善宫颈癌患者临床结局预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Resistance to chemo-radiation therapy is a substantial obstacle that compromises treatment of advanced cervical cancer. The objective of this study was to investigate if a proteomic panel associated with radioresistance could predict survival of patients with locally advanced cervical cancer. METHODS: A total of 181 frozen tissue samples were prospectively obtained from patients with locally advanced cervical cancer before chemoradiation. Expression levels of 22 total and phosphorylated proteins were evaluated using well-based reverse phase protein arrays. Selected proteins were validated with western blotting analysis and immunohistochemistry. Performances of models were internally and externally validated. RESULTS: Unsupervised clustering stratified patients into three major groups with different overall survival (OS, P = 0.001) and progression-free survival (PFS, P = 0.003) based on detection of BCL2, HER2, CD133, CAIX, and ERCC1. Reverse-phase protein array results significantly correlated with western blotting results (R2 = 0.856). The C-index of model was higher than clinical model in the prediction of OS (C-index: 0.86 and 0.62, respectively) and PFS (C-index: 0.82 and 0.64, respectively). The Kaplan-Meier survival curve showed a dose-dependent prognostic significance of risk score for PFS and OS. Multivariable Cox proportional hazard model confirmed that the risk score was an independent predictor of PFS (HR: 1.6; 95% CI: 1.4-1.9; P < 0.001) and OS (HR: 2.1; 95% CI: 1.7-2.5; P < 0.001). CONCLUSION: A proteomic panel of BCL2, HER2, CD133, CAIX, and ERCC1 independently predicted survival in locally advanced cervical cancer patients. This prediction model can help identify chemoradiation responsive tumors and improve prediction for clinical outcome of cervical cancer patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Choi CH, Chung JY, Kang JH, et al. Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer. Gynecol Oncol. 2020. PMID: 32107047. doi:10.1016/j.ygyno.2020.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。